A new clinical trial is under preparation, and scientists from the UK are recruiting patients with Crohn's disease, hoping to test whether stem cell transplants can restart their immune system and improve their response to medication. The study will benefit 115,000 Britons, and if the experiment is successful, more people will gain new vitality.
In theory, Crohn's disease is a long-term autoimmune disease that causes inflammation of the digestive system and causes diarrhea, abdominal pain, extreme fatigue and other serious symptoms. Scotland is one of the countries with the highest incidence of Crohn's disease in the world. In the past 25 years in Scotland, the number of children under the age of 16 diagnosed with this disease has soared by 750%, but the cause has not been found.
The current clinical trial, called "ASTIClite," is a follow-up to the team's 2015 "ASTIC" trial, which examined similar stem cell therapies. Although the initial treatment failed to cure the disease, the team found that the patient's condition was greatly improved, proving the rationality of further clinical trials. However, the current difficulties are not only the problem of efficacy, but some patients have the risk of more serious side effects, including independent experiments, which are urgent problems for the treatment team.